Patents Assigned to NTK Enterprises, Inc.
-
Patent number: 8603081Abstract: One or more treatment parameters are determined for a cornea reshaping procedure. The one or more treatment parameters are selected so as to reduce an amount of collagen shrinkage in a cornea of a patient's eye caused by the cornea reshaping procedure. For example, the one or more treatment parameters could be selected so as to minimize an amount of stromal collagen shrinkage in the cornea of the patient's eye caused by the cornea reshaping procedure. As another example, the cornea reshaping procedure could include irradiating multiple spots on the cornea of the patient's eye, where each spot is associated with an amount of stromal collagen. The one or more treatment parameters could be selected so that no more than 1% or 5% of the stromal collagen in the irradiated spots undergoes clinically significant shrinkage as a result of the cornea reshaping procedure.Type: GrantFiled: August 14, 2008Date of Patent: December 10, 2013Assignee: NTK Enterprises, Inc.Inventor: Michael J. Berry
-
Publication number: 20130110091Abstract: A system includes at least one radiation source configured to generate radiation for a cornea reshaping procedure and a corneal cross-linking procedure. The system also includes a delivery device configured to deliver the radiation to the patient's eye. The system further includes a controller configured to control the delivery of the radiation to the patient's eye during the cornea reshaping procedure and the corneal cross-linking procedure. The controller may be configured to control the delivery of radiation so that the cornea reshaping procedure and the corneal cross-linking procedure at least partially overlap in time. The delivery device may be configured to deliver radiation to specified areas of the patient's eye during the cornea reshaping procedure and to deliver radiation only to the same specified areas of the patient's eye during the corneal cross-linking procedure.Type: ApplicationFiled: October 9, 2012Publication date: May 2, 2013Applicant: NTK Enterprises, Inc.Inventor: NTK Enterprises, Inc.
-
Patent number: 7691099Abstract: A deuterated ocular solution is applied to an eye. The deuterated ocular solution includes deuterated water and one or more ocular drugs (such as proparacaine). A protective corneal device is applied to a cornea of the eye. The device includes a window configured to contact at least a portion of the cornea. At least part of the cornea is irradiated using light energy that passes through the window during a cornea reshaping procedure, where the window is substantially transparent to the light energy. The window of the protective corneal device and the deuterated ocular solution may prevent clinically significant damage to a corneal epithelium of the cornea during the cornea reshaping procedure, such as by preventing a temperature of the corneal epithelium from exceeding approximately 70° C. during the cornea reshaping procedure. This may help to avoid a wound healing response in the eye and an associated regression of refractive correction.Type: GrantFiled: July 9, 2007Date of Patent: April 6, 2010Assignee: NTK Enterprises, Inc.Inventor: Michael J. Berry
-
Publication number: 20090054879Abstract: One or more treatment parameters are determined for a cornea reshaping procedure. The one or more treatment parameters are selected so as to reduce an amount of collagen shrinkage in a cornea of a patient's eye caused by the cornea reshaping procedure. For example, the one or more treatment parameters could be selected so as to minimize an amount of stromal collagen shrinkage in the cornea of the patient's eye caused by the cornea reshaping procedure. As another example, the cornea reshaping procedure could include irradiating multiple spots on the cornea of the patient's eye, where each spot is associated with an amount of stromal collagen. The one or more treatment parameters could be selected so that no more than 1% or 5% of the stromal collagen in the irradiated spots undergoes clinically significant shrinkage as a result of the cornea reshaping procedure.Type: ApplicationFiled: August 14, 2008Publication date: February 26, 2009Applicant: NTK Enterprises, Inc.Inventor: Michael J. Berry
-
Publication number: 20080027418Abstract: A deuterated ocular solution is applied to an eye. The deuterated ocular solution includes deuterated water and one or more ocular drugs (such as proparacaine). A protective corneal device is applied to a cornea of the eye. The device includes a window configured to contact at least a portion of the cornea. At least part of the cornea is irradiated using light energy that passes through the window during a cornea reshaping procedure, where the window is substantially transparent to the light energy. The window of the protective corneal device and the deuterated ocular solution may prevent clinically significant damage to a corneal epithelium of the cornea during the cornea reshaping procedure, such as by preventing a temperature of the corneal epithelium from exceeding approximately 70° C. during the cornea reshaping procedure. This may help to avoid a wound healing response in the eye and an associated regression of refractive correction.Type: ApplicationFiled: July 9, 2007Publication date: January 31, 2008Applicant: NTK Enterprises, Inc.Inventor: Michael Berry
-
Publication number: 20060287662Abstract: A system includes a light source operable to generate light energy for a cornea reshaping procedure. The system also includes a device operable to be attached to an eye having a cornea. The device includes a window operable to contact at least a portion of the cornea. The window is substantially transparent to the light energy that irradiates the cornea during the cornea reshaping procedure. The window is also operable to cool at least a portion of a corneal epithelium in the cornea during the cornea reshaping procedure. The window may be operable to prevent clinically significant damage to the corneal epithelium during the cornea reshaping procedure. The window may be operable to prevent a temperature of the corneal epithelium from exceeding a damage threshold temperature during the cornea reshaping procedure, such as a damage threshold temperature of approximately 70° C.Type: ApplicationFiled: May 25, 2006Publication date: December 21, 2006Applicant: NTK Enterprises, Inc.Inventors: Michael Berry, Benjamin Woodward